First Patient in BTKi Combination Cohort of azer-cel study
Open PDF
| Stock | Imugene Ltd (IMU.ASX) |
|---|---|
| Release Time | 28 May 2026, 9:41 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Imugene Doses First Patient in BTKi Combination Cohort of azer-cel Phase 1b Study
Key Points
- First patient dosed in BTKi combination cohort of azer-cel Phase 1b study
- Patient with Mantle Cell Lymphoma (MCL) who failed prior BTKi therapy
- Aim to explore improved activity of azer-cel and BTKi in combination
Full Summary
Imugene Limited (ASX: IMU) has announced the enrollment of the first patient in the BTK inhibitor (BTKi) combination cohort of its ongoing Phase 1b basket study of azer-cel, an off-the-shelf CAR T cell therapy. The patient, diagnosed with Mantle Cell Lymphoma (MCL) and having failed prior BTKi therapy, is part of a cohort evaluating the safety and preliminary efficacy of azer-cel in combination with a BTKi. This expansion of the clinical scope aims to explore whether concurrent treatment may enhance the activity of azer-cel and BTKi, addressing a significant unmet medical need as many patients develop resistance or intolerance to BTKi therapy.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In